Cerebral ALD's Narrow Window: Treat an Asymptomatic Boy, or Watch and Risk Missing It
A boy with X-linked adrenoleukodystrophy has early MRI changes but no symptoms at all. Both gene therapy and transplant only work before real neurologic damage sets in — but most boys with early lesions like his never progress to cerebral disease. Treat the MRI, or watch the boy?
C.W. is seven years old and has been followed in this clinic since he was two, when an older half-brother's diagnosis of childhood cerebral ALD — which came only after months of declining school performance were mistaken for attention problems — prompted family cascade testing and identified C.W.'s own ABCD1 mutation before he had shown a single symptom. For five years that surveillance meant what it was designed to mean: normal MRIs, normal neuropsychological testing, an active kid who plays trumpet in his school band. He has primary adrenal insufficiency on stable hydrocortisone, which is common in ALD and says nothing about his brain.
His six-month surveillance MRI, reviewed today, is the first to change. There is a small area of white matter signal abnormality in the parieto-occipital region, corresponding to a Loes score of 3 — low, but no longer zero. It enhances with gadolinium. That second detail is not incidental description; enhancement is what distinguishes active demyelination from a lesion that is merely present, and it is the finding that converts him from a boy under surveillance into a boy with a treatment decision. His neurologic exam is completely normal, with no cognitive, visual, auditory, or behavioral change, which on the standard scoring makes his neurologic function score zero.
Read against the labeled criteria rather than against the disease in general, those three facts place him exactly. Elivaldogene autotemcel is indicated for boys aged 4 to 17 with a Loes score between 0.5 and 9, gadolinium enhancement on MRI, and a neurologic function score of 1 or lower. C.W. is 7, scores 3, enhances, and functions at zero. He is not near the edge of that window; he is squarely inside it, and today is the first day he has been. The same early phase is when allogeneic transplant works best, and the Lenti-D trial (Eichler et al., 2017) enrolled on essentially these criteria, finding most treated boys alive and free of major functional disability at two years.
Being inside the window is what makes the next question urgent rather than academic, and it is not which treatment to prefer. The gene therapy is licensed only for boys who have no available HLA-matched donor, so donor status determines which options exist for him before anyone weighs risk profiles against each other, and his has never been established. Cutting the other way: not every boy with an early lesion progresses, and natural-history cohorts describe a meaningful fraction with similar findings who never reach the cerebral phenotype. Treating today commits a currently well, asymptomatic seven-year-old to myeloablative conditioning for a trajectory not yet certain to be his.
At the ALD surveillance clinic, six-month MRI review
I think this is exactly the moment to act, not wait for more certainty. Cerebral ALD's treatment window is real and it closes fast — both gene therapy and transplant work best at low Loes scores in neurologically asymptomatic boys, and their effectiveness drops sharply once real white matter involvement and symptoms set in. That's the whole basis of the Lenti-D program's entry criteria — Eichler and colleagues in 2017 enrolled boys at Loes 9 or below with no major functional disability, precisely because that's the window where either treatment still holds. His Loes score just moved from zero to three. That's the earliest possible signal this disease is actually asking us for the thing we've been watching five years for. I don't think 'he still looks completely normal' should be read as reassuring here — his brother's decline started exactly this way, as an MRI finding well before anyone could see it in the classroom.
If his MRI had stayed clean today, I would be telling you to keep watching, not to treat — I'm not arguing for treating every ALD boy preemptively, only that a confirmed new lesion at Loes 3 is the specific signal this surveillance protocol exists to catch.
You're right that the window is real and that his brother's course is a legitimate reason for real concern, not complacency. But I don't think a Loes score of 3 with a completely normal neurologic exam is the same thing as confirmed progressive cerebral disease, and I want us to be honest that the natural-history work — Moser's Kennedy Krieger cohort is the one everybody cites here — describes a meaningful fraction of boys with early MRI change who never go on to the progressive cerebral phenotype at all. Both of our treatment options carry serious risk — myeloablative conditioning itself is not a small thing to put a well seven-year-old through, on top of whichever specific treatment-related risk we're discussing. I'd want a repeat MRI at a much shorter interval, six to eight weeks rather than six months, before committing him to either option.
'The window closes fast, so act now' assumes his lesion is already on the progressive trajectory — but that's exactly the fact we don't yet have. A short-interval repeat MRI costs weeks, not the months his brother's story might suggest, and would tell us whether this is truly progressing before we commit him to a treatment carrying its own serious, non-hypothetical risk.
I don't have a strong view on the timing question the two of you are actually disagreeing about, and I think a short-interval repeat MRI is a reasonable way to get more information before this family has to decide. But I want to correct something that I think is getting collapsed together, because it changes what we should be doing this week regardless of how the timing question lands. Gene therapy and allogeneic transplant are not two co-equal options we choose between on preference. Elivaldogene autotemcel is labeled only for boys with early active CALD who do not have an available HLA-matched donor — it is a second-line option by indication, not an alternative to transplant. And the reason for that restriction has gotten stronger, not weaker: it carries a boxed warning for hematologic malignancy from lentiviral insertion, and as of last year the FDA reported myelodysplastic syndrome or acute myeloid leukemia in ten of sixty-seven trial participants, about fifteen percent, up from three at the time of approval. The agency has explicitly told us to consider allogeneic transplant first where a matched donor exists. Allogeneic transplant has a longer track record without that specific malignancy signal, though it brings real graft-versus-host disease and treatment-related mortality risk of its own. The operative point is that we have not yet confirmed whether he has a matched donor — and that single unanswered question, not our preference between modalities, is what determines which of these two he is actually eligible for.
So whichever timing this family ultimately chooses, the donor search should start now rather than after the next MRI — it is the thing that decides his options, it takes weeks we may not want to spend later, and skipping it in favor of the therapy that doesn't require it would have us reaching for the donor-less option for a boy who may not be donor-less. This family deserves to hear both risk profiles stated plainly, and to hear that one of the two paths may not be open to him at all.
Not agreed, and stated as such rather than smoothed into false consensus: the neurologist and hematologist-oncologist left this meeting with genuinely different comfort levels about how much certainty is needed before committing a currently well, asymptomatic boy to either treatment. What was agreed for C.W. specifically was a repeat MRI at six to eight weeks rather than the standard six-month interval, with an explicit understanding that a confirmed further increase in Loes score or any new neurologic finding at that visit would move the team directly to treatment rather than reopening the timing debate a second time. Agreed without dissent, and started immediately rather than deferred to that visit: HLA typing and a formal donor search, since elivaldogene autotemcel is labeled only for boys without an available matched donor, and whether he has one determines which treatments are open to him before any discussion of which to prefer.